Antroquinonol: meta-analysis of COVID-19 studies

All studies Hospitalization Serious outcomes Recovery Viral clearance RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Hospitalization (1)2%

Viral clearance (1)7%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Antroquinonol
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Antroquinonol COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)−200%3.00 · 0.12–72.25progression1/620/62

Late treatment−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.51

All studies−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)2%0.98 · 0.75–1.30hosp. time60 (n)62 (n)

Late treatment2%0.98 · 0.75–1.3060 (n)62 (n)2% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.92

All studies2%0.98 · 0.75–1.3060 (n)62 (n)2% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.9200.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)−200%3.00 · 0.12–72.25progression1/620/62

Late treatment−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.51

All studies−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)−17%1.17 · 0.53–2.58recov. time62 (n)62 (n)

Late treatment−17%1.17 · 0.53–2.5862 (n)62 (n)17% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.72

All studies−17%1.17 · 0.53–2.5862 (n)62 (n)17% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7200.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)7%0.93 · 0.43–2.00viral time62 (n)62 (n)

Late treatment7%0.93 · 0.43–2.0062 (n)62 (n)7% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.87

All studies7%0.93 · 0.43–2.0062 (n)62 (n)7% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.8700.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)−200%3.00 · 0.12–72.25progression1/620/62

Late treatment−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.51

All studies−200%3.00 · 0.12–72.251/620/62200% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →

c19early.org

October 2026

Antroquinonol COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cheng (DB RCT)−200%3.00 · 0.12–72.25progression1/620/62 Cheng (DB RCT)−17%1.17 · 0.53–2.58recov. time62 (n)62 (n) Cheng (DB RCT)6%0.94 · 0.77–1.14recov. time62 (n)62 (n) Cheng (DB RCT)2%0.98 · 0.75–1.30hosp. time60 (n)62 (n) Cheng (DB RCT)7%0.93 · 0.43–2.00viral time62 (n)62 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Antroquinonol
reduces riskAntroquinonol
increases risk →